Axon Clinical s.r.o.

Running trials

• Not yet recruiting

  A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study

  2026-526648-11-00· Phase 2/3· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Source

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

  NCT07705555· Phase 3· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  2025-523938-10-00· Phase 3· Source

• Recruiting

  Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Phase 3· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Source

• Recruiting

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· Phase 2· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Source

• Active, not recruiting

  A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· Phase 2· Source

• Recruiting

  A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Phase 2/3· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Source

• Active, not recruiting

  ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

  NCT06373731· Phase 3· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

  NCT06063967· Phase 3· Source

• Active, not recruiting

  Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

  NCT05949593· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration6 recruiting
• Crohn's disease3 recruiting
• Diabetic eye disease3 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Source

• Completed

  A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

  NCT06591598· Phase 4· Source

• Completed

  A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

  2023-507207-66-00· Phase 3· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Completed

  A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT05019521· Phase 2· Source

• Completed

  A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration

  NCT04757636· Phase 3· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· Source